tetano
Editor, Senior Moderator
doi:10.1016/j.vaccine.2011.02.094 | How to Cite or Link Using DOI
Copyright ? 2011 Published by Elsevier Ltd.
Antibody responses to natural influenza A/H1N1/09 disease or following immunization with adjuvanted vaccines, in immunocompetent and immunocompromised children
References and further reading may be available for this article. To view references and further reading you must purchase this article.
Sara Meiera, b, Michael Bela, Arnaud L?Huilliera, b, Pierre-Alex Crisinelb, Christophe Combescurec, Laurent Kaiserd, St?phane Grilleta, Klara P?sfay-Barbeb, Claire-Anne Siegrista, Corresponding Author Contact Information, E-mail The Corresponding Author and with the H1N1 Epidemiology Study Group of Geneva1
a Center for Vaccinology and Neonatal Immunology, Department of Pediatrics and Pathology-Immunology, University Hospitals of Geneva & Faculty of Medicine, University of Geneva, Switzerland
b Pediatric Clinical Research Platform, Department of Pediatrics, University Hospitals of Geneva & Faculty of Medicine, University of Geneva, Switzerland
c Clinical Research Center, University Hospitals of Geneva & Faculty of Medicine, University of Geneva, Switzerland
d Laboratory of Virology and Swiss National Center for Influenza, Department of Genetics and Laboratory Medicine, University Hospitals of Geneva & Faculty of Medicine, University of Geneva, Switzerland
Received 8 January 2011;
revised 10 February 2011;
accepted 26 February 2011.
Available online 17 March 2011.
Abstract
Objectives
To compare antibody responses elicited by influenza A/H1N1/09 disease and immunization with adjuvanted vaccines, in immunocompetent or immunocompromised children.
Study design
Prospective parallel cohort field study enrolling children with confirmed influenza A/H1N1/09 disease or immunized with 1 (immunocompetent) or 2 (immunocompromised) doses of influenza A/H1N1/09 squalene-based AS03- or MF59-adjuvanted vaccines. Antibody geometric mean titers (GMT) were measured by hemagglutination inhibition (HAI) and microneutralization (MN) assays 4?6 weeks after vaccination/disease. Vaccine adverse events were self-recorded in a 7-day diary.
Results
Antibody titers were as high in 48 immunocompetent children after a single immunization (HAI and MN seroprotection rates: 98%; HAI-GMT: 395, MN-GMT: 370) as in 51 convalescent children (seroprotection rates: 98% (HAI) and 92% (MN); GMT: 350 (HAI) and 212 (MN). Twenty-seven immunocompromised children reached slightly lower seroprotection rates (HAI: 89%, MN: 85%) but similar antibody titers (HAI-GMT: 306, MN-GMT: 225) after 2 immunizations. Adverse events increased with age (P = 0.01) and were more frequent with Pandemrix? than Focetria? (P = 0.03).
Conclusions
Similarly high seroresponses may be expected in immunocompetent children after a single dose of adjuvanted vaccines as responses of convalescent children. Two vaccine doses were sufficient for most immunocompromised children.
http://www.sciencedirect.com/scienc...e364545e643b8a32e958434cfb4f54e8&searchtype=a
Copyright ? 2011 Published by Elsevier Ltd.
Antibody responses to natural influenza A/H1N1/09 disease or following immunization with adjuvanted vaccines, in immunocompetent and immunocompromised children
References and further reading may be available for this article. To view references and further reading you must purchase this article.
Sara Meiera, b, Michael Bela, Arnaud L?Huilliera, b, Pierre-Alex Crisinelb, Christophe Combescurec, Laurent Kaiserd, St?phane Grilleta, Klara P?sfay-Barbeb, Claire-Anne Siegrista, Corresponding Author Contact Information, E-mail The Corresponding Author and with the H1N1 Epidemiology Study Group of Geneva1
a Center for Vaccinology and Neonatal Immunology, Department of Pediatrics and Pathology-Immunology, University Hospitals of Geneva & Faculty of Medicine, University of Geneva, Switzerland
b Pediatric Clinical Research Platform, Department of Pediatrics, University Hospitals of Geneva & Faculty of Medicine, University of Geneva, Switzerland
c Clinical Research Center, University Hospitals of Geneva & Faculty of Medicine, University of Geneva, Switzerland
d Laboratory of Virology and Swiss National Center for Influenza, Department of Genetics and Laboratory Medicine, University Hospitals of Geneva & Faculty of Medicine, University of Geneva, Switzerland
Received 8 January 2011;
revised 10 February 2011;
accepted 26 February 2011.
Available online 17 March 2011.
Abstract
Objectives
To compare antibody responses elicited by influenza A/H1N1/09 disease and immunization with adjuvanted vaccines, in immunocompetent or immunocompromised children.
Study design
Prospective parallel cohort field study enrolling children with confirmed influenza A/H1N1/09 disease or immunized with 1 (immunocompetent) or 2 (immunocompromised) doses of influenza A/H1N1/09 squalene-based AS03- or MF59-adjuvanted vaccines. Antibody geometric mean titers (GMT) were measured by hemagglutination inhibition (HAI) and microneutralization (MN) assays 4?6 weeks after vaccination/disease. Vaccine adverse events were self-recorded in a 7-day diary.
Results
Antibody titers were as high in 48 immunocompetent children after a single immunization (HAI and MN seroprotection rates: 98%; HAI-GMT: 395, MN-GMT: 370) as in 51 convalescent children (seroprotection rates: 98% (HAI) and 92% (MN); GMT: 350 (HAI) and 212 (MN). Twenty-seven immunocompromised children reached slightly lower seroprotection rates (HAI: 89%, MN: 85%) but similar antibody titers (HAI-GMT: 306, MN-GMT: 225) after 2 immunizations. Adverse events increased with age (P = 0.01) and were more frequent with Pandemrix? than Focetria? (P = 0.03).
Conclusions
Similarly high seroresponses may be expected in immunocompetent children after a single dose of adjuvanted vaccines as responses of convalescent children. Two vaccine doses were sufficient for most immunocompromised children.
http://www.sciencedirect.com/scienc...e364545e643b8a32e958434cfb4f54e8&searchtype=a